Jun 26, 2019 by Brian Orelli, PhDThe 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)Some of the drugs aren't going to survive this marriage.
Jun 21, 2019 by Brian Orelli, PhDOh, By the Way, This Clinical Trial Didn't WorkSometimes, you hear the bad news from a friend of a friend.
Jun 20, 2019 by Brian Orelli, PhD3 Drugs Under FDA Review With Blockbuster PotentialThese follow-on drugs are on a path to upend the current standards of care.
Jun 20, 2019 by Brian Orelli, PhDWhat Should Celgene's Investors Do With Everything Bristol-Myers Squibb Is Giving Them?Shareholders get an all-or-nothing $9 contingent value right (CVR) when the acquisition closes.
Jun 18, 2019 by Brian Orelli, PhDHere's Why Biohaven Pharmaceutical Plummeted TodayDilution is coming for shareholders, while an acquisition doesn't seem as likely.
Jun 10, 2019 by Brian Orelli, PhDHere's Why Regeneron Pharmaceuticals Tumbled 12% in MaySales growth is slowing, and there's an issue with one of the biotech's pipeline drugs.
Jun 7, 2019 by Brian Orelli, PhDHere's Why La Jolla Pharmaceutical Has More Than Doubled Over the Last 2 DaysA mid-stage clinical trial has investors excited about the biotech's future.
May 30, 2019 by Brian Orelli, PhDHere's Why Shares of MiMedx Group Jumped Higher TodayA new board could signify the start of a turnaround.
May 16, 2019 by Brian Orelli, PhDBecton, Dickinson Muscles Through a Tough QuarterThings should pick up in the back half of the fiscal year.
May 14, 2019 by Brian Orelli, PhDIonis Pharmaceuticals Is 40% of the Way ThereA large licensing payment from one of the biotech's partners drives revenue growth.
May 14, 2019 by Brian Orelli, PhDGenomic Health's Strong Growth Spooks InvestorsA good start to the year and no increased guidance mean slower growth ahead.
May 13, 2019 by Brian Orelli, PhDWaiting on Diplomat Pharmacy to RebuildIt'll be a few months before the company can secure new clients for its pharmacy benefit manager business.
May 13, 2019 by Brian Orelli, PhDQiagen Looks to Growth in the Second Half of the YearThe QIAstat should accelerate growth for the diagnostic testing company.
May 10, 2019 by Brian Orelli, PhDHere's Why ShockWave Medical Jumped for a Second Straight DayThe medical device maker is on fire.
May 9, 2019 by Brian Orelli, PhDHere's Why ShockWave Medical Jumped Higher TodayThe medical-device maker is off to a good start as a public company.
May 9, 2019 by Brian Orelli, PhDNovo Nordisk Trots Along Waiting for Its Next-Generation Oral DrugOral semaglutide is on its way.
May 8, 2019 by Brian Orelli, PhDEmergent BioSolutions Negotiates for a Strong Second HalfA new government contract for smallpox vaccine, ACAM2000, is still in the works.
May 8, 2019 by Brian Orelli, PhDHere's Why Shares of Genomic Health Dropped TodayAfter Genomic's stellar first quarter, investors are getting jittery about growth in the second half.
May 7, 2019 by Brian Orelli, PhDMomenta Pharmaceuticals Wants to Be the "Humira of the FcRn Space"It's going to take a few years to get there.
